Cargando…
ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer
Autores principales: | Petit, Robert G, Mehta, Ajay, Jain, Minish, Gupta, Sudeep, Nagarkar, Rajnish, Kumar, Vijay, Premkumar, Sumana, Neve, Rakesh, John, Subhashini, Basu, Partha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288775/ http://dx.doi.org/10.1186/2051-1426-2-S3-P92 |
Ejemplares similares
-
A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
por: Basu, Partha, et al.
Publicado: (2018) -
ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer
por: Petit, Robert G, et al.
Publicado: (2013) -
Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy
por: Miles, Brett A., et al.
Publicado: (2017) -
Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001
por: Miles, Brett, et al.
Publicado: (2017) -
Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy
por: Molli, Poonam, et al.
Publicado: (2013)